CD274 and neoplasm: Tumors exhibiting positive expression of PD-L1 or microsatellite instable (MSI) demonstrated a higher level of responsiveness to the NICT regimen.<h4>Conclusions</h4>Immunotherapy-based neoadjuvant regimens exhibit an enhanced potential for promoting tumor regression; however, caution is warranted due to the elevated risk of severe TRAEs.